Prandial Orientated Biphasic Insulin Aspart 30 Therapy - the Physiological Premix Insulin Therapy for Type 2 Diabetes
- Registration Number
- NCT01536652
- Lead Sponsor
- Novo Nordisk A/S
- Brief Summary
This study is conducted in Europe. The aim of this observational study is to document the glycaemic parameters, adverse events, including drug reactions, as well as hypoglycaemic episodes, in patients that switched from insulin glargine combined with oral antidiabetic drugs (OADs) to biphasic insulin aspart 30 (NovoMix® 30) combined with OADs, when applicable.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 4994
Inclusion Criteria
- Subjects with diabetes mellitus type 2
Read More
Exclusion Criteria
Not provided
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description BIAsp 30 users biphasic insulin aspart 30 -
- Primary Outcome Measures
Name Time Method HbA1c (glycosylated haemoglobin)
- Secondary Outcome Measures
Name Time Method Insulin dosage Incidence of (serious) adverse drug reactions Incidence of hypoglycaemic episodes Body weight Preprandial and postprandial blood glucose values (self measured)